ADITYAB,SARAM T,DELPHINEL, et al. Sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (pts) with previously treated,metastatic triple-negative breast cancer (mTNBC):final results from the phase 3 ASCENT study[EB/OL].( 2022-06-02)[2023-11-22].https://m...
Treatment of Advanced Breast Cancer (ABC): The Expanding Landscape of Targeted TherapiesBreast cancer is the most common cancer in womenworldwide [1]. It is becoming clear that the marked heterogeneityin breast cancer spreads beyond those defined by routinehistology and immunohistochemistry used for ...
2. Principles for disease assessment of advanced breast cancer 3. Principles for ABC treatment 4. Treatment of unresectable locally advanced breast cancer 5. General principles of chemotherapy for ABC 6. Treatment for HR+ and HER2- ABC 7. Treatment for HER2-positive ABC 8. Treatment for advanced...
Medically Reviewed byJabeen Begum, MDon September 18, 2023 Written bySusan Bernstein 1/7 Set Your Boundaries Protect yourself. You're more vulnerable right now. Before cancer, self-care was not in my vocabulary. I was a class mother, worked 60 hours a week. Now, I've changed. Learn how...
The choice of treatment regimens for patients with advanced breast cancer is very important, and the optimal treatment strategy beyond the first- and second-line therapy is often lacking. Herein, the China Advanced Breast Cancer Guideline Panel discussed and summarized recent clinical evidence, ...
STEAP1 is broadly expressed in treatment-refractory mCRPC tissues We first set out to determine the pattern and extent of STEAP1 expression relative to PSMA in advanced metastatic prostate cancer. We performed immunohistochemical (IHC) staining on a duplicate set of tissue microarrays consisting of 12...
Journal: Cancer Treatment Reviews Publisher: Elsevier BV Read this article at ScienceOpenPublisherPubMed Review Bookmark Cite as... There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist ...
Vepdegestrant continued to showcase clinical activity with favorable tolerability spanning all doses examined in heavily pretreated patients with estrogen receptor–positive, HER2-negative advanced breast cancer, according to updated dose-escalation data
Immunotherapy, as a powerful strategy for cancer treatment, has achieved tremendous efficacy in clinical trials. Despite these advancements, there is much to do in terms of enhancing therapeutic benefits and decreasing the side effects of cancer immunoth
“The survival data in this heavily pre-treated advanced metastatic breast cancer patients looks very promising and we are looking forward to validate these findings in the PREVAIL trial “Importantly, the favorable safety profile makes the novel t...